Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss in People With Obesity: Study

A once-weekly injectable recently approved to treat type 2 diabetes may hold major potential as a weight loss medication for people with obesity, too, a study suggests.

Overweight or obese participants without type 2 diabetes who took the drug, called tirzepatide (sold as the diabetes drug Mounjaro), lost an average of nearly 21 percent of their body weight at the highest dose studied. Scientists presented their findings at the American Diabetes Association (ADA)’s annual meeting in New Orleans and published the study in The New England Journal of Medicine.

“Definitely, the weight loss in this study is far more what we had ever seen with other FDA-approved medications in term of the absolute amount of weight lost or percentage of weight lost,” says Osama Hamdy, MD, PhD, an associate professor at Harvard Medical School and medical director of the obesity clinical program at the Joslin Diabetes Center in Boston. Dr. Hamdy wasn’t involved in the new trial; he has received funding from Eli Lilly, the maker of tirzepatide.

Analyzing Tirzepatide for Weight Loss

The trial enrolled 2,539 adults who weighed an average of 231 pounds and had a body mass index (BMI) of 38 to start. A BMI of 30 or higher is considered obesity, and 95 percent had a BMI at least this high.


Leave a Reply

Your email address will not be published.